Key facts
- This page summarizes Karen J. Wilson's Form 3 filing for Connect Biopharma Holdings Ltd (CNTB).
- 0 reported transactions and 6 derivative rows are listed below.
- Accepted by SEC: 16 Mar 2026, 16:43.
Karen J. Wilson - 16 Mar 2026 Form 3 Insider Report for Connect Biopharma Holdings Ltd (CNTB)
- Reporting relationship
- Director
- Issuer ticker
- CNTB
- Reported as of
- 16 Mar 2026
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 16 Mar 2026, 16:43:10 UTC
- Prior SEC filing
- 17 Nov 2025
- Next SEC filing
- 26 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lisa Peraza attorney-in-fact for Karen J Wilson
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Karen J. Wilson filed Form 3 for Connect Biopharma Holdings Ltd (CNTB) on 16 Mar 2026.
Change
- Previous filing in this sequence was filed on 17 Nov 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001267490
Primary reporting owner
WILSON KAREN J
- Relationship
- Director
- Address
- 3580 CARMEL MOUNTAIN ROAD, SUITE 200, SAN DIEGO
- Signature
- /s/ Lisa Peraza attorney-in-fact for Karen J Wilson
- Signature date
- 16 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CNTB
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 10,000
- Date
- 16 Mar 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CNTB
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 16 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 89,220
- Exercise price
- $8.16
- Footnotes
- F1
CNTB
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 16 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 21,269
- Exercise price
- $4.12
- Footnotes
- F1
CNTB
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 16 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 21,269
- Exercise price
- $1.27
- Footnotes
- F1
CNTB
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 16 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 26,450
- Exercise price
- $1.18
- Footnotes
- F1
CNTB
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 16 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 60,000
- Exercise price
- $0.9600
- Footnotes
- F1
CNTB
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 16 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 60,000
- Exercise price
- $2.50
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The stock option is fully vested and exercisable.
Footnote F2
The stock option fully vests and becomes exercisable on March 2, 2027.